Sylogist Ltd. (TSE:SYZ - Free Report) - Analysts at Stifel Canada decreased their Q2 2025 earnings per share (EPS) estimates for Sylogist in a research report issued on Thursday, May 15th. Stifel Canada analyst S. Sukumar now anticipates that the company will post earnings per share of $0.00 for the quarter, down from their prior estimate of $0.05. The consensus estimate for Sylogist's current full-year earnings is $0.24 per share. Stifel Canada also issued estimates for Sylogist's Q3 2025 earnings at $0.04 EPS and Q4 2025 earnings at $0.08 EPS.
Sylogist Stock Performance
Shares of TSE SYZ opened at C$9.53 on Monday. The company has a debt-to-equity ratio of 47.19, a current ratio of 0.54 and a quick ratio of 0.51. The firm has a market cap of C$225.34 million, a price-to-earnings ratio of 211.49 and a beta of 0.82. The stock's fifty day moving average price is C$8.43 and its two-hundred day moving average price is C$9.30. Sylogist has a one year low of C$6.33 and a one year high of C$11.60.
Sylogist Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Wednesday, March 12th. Investors of record on Wednesday, March 12th were paid a $0.01 dividend. The ex-dividend date was Friday, February 28th. This represents a $0.04 annualized dividend and a dividend yield of 0.42%. Sylogist's dividend payout ratio (DPR) is presently 88.77%.
About Sylogist
(
Get Free Report)
Sylogist Ltd., a software company, provides mission-critical software-as-a-service solutions in Canada, the United States, and the United Kingdom. The company offers SylogistMission constituent relationship management system, which includes donor management, fundraising, volunteer management, and program delivery; and enterprise resource management, such as accounting and financial management, grant and award management, budget management, payroll and human resources, analytics and reporting, and support and training.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sylogist, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sylogist wasn't on the list.
While Sylogist currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
